Table 1.
Characteristics by group.
Fig 1.
Kaplan–Meier curves showing the onset of fractures.
Table 2.
Risk of fracture with competing risk in denosumab users versus non-users.
Fig 2.
Kaplan–Meier curves for all-cause mortality.
Table 3.
Survival analysis in denosumab users versus non-users.
Fig 3.
Kaplan–Meier curve for mortality related to CVD.
Fig 4.
Kaplan–Meier curves for mortality related to infectious disease.